EarlySense announced today that its new EverOn Touch system has been cleared for marketing by the US Food and Drug Administration (FDA).
The FDA clearance covers several additions to the earlier EverOn contact-free patient supervision system. The system now includes an online display that alerts medical staff regarding a patient’s motion level and verifies patient turns as indicated by nurses. Identifying low patient movement and then turning patients methodically are key elements in the prevention of pressure ulcers, which EarlySense calls the most costly patient safety risk in US hospitals.
EarlySense CEO Avner Halperin said, "Today’s FDA clearance news further validates our technology. We have repeatedly heard from our partner hospitals that preventing pressure ulcers is a critical need due to the enormous burden pressure ulcers place on hospital budgets and the huge task of preventing them. The addition of pressure ulcer prevention support capabilities to a system that already delivers vital sign detection and bed exit alerts further enhances the EverOn as a full contact-free patient safety suite for hospitalized patients.”
The newly cleared features augment the previously FDA-approved EverOn contact-free, patient supervision system which utilizes a sensor placed underneath a hospital bed mattress. EverOn detects heart and respiration rates, bed entries and exits. The system is currently installed at several medical centers in the USA and Europe.
EarlySense is headquartered in Ramat-Gan. In early June, the company raised $13 million in its third financing round. Pitango Venture Capital led that round, joined by the previous investors, including ProSeed Venture Capital Fund (TASE:PRSD).
Published by Globes [online], Israel business news - www.globes-online.com - on June 21, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010